Develops therapies for autoimmune diseases and cancer, focusing on immune modulation and targeted therapies.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company based in Encinitas, California, focuses on developing and commercializing innovative therapies for ophthalmic diseases across the United States.
The company's flagship product, KIO-301, represents a potential breakthrough in vision restoration. Currently in Phase 1 clinical trials, KIO-301 utilizes a novel photoswitch mechanism designed to restore vision in patients affected by inherited and age-related degenerative retinal diseases. Kiora Pharmaceuticals is also advancing KIO-101, an eye drop formulation undergoing Phase 2 clinical trials for treating the ocular manifestations of rheumatoid arthritis and non-infectious posterior uveitis. Additionally, KIO-201, another eye drop candidate, is in Phase 3 clinical trials aimed at enhancing corneal wound repair following PRK surgery.
Originally established as Eyegate Pharmaceuticals, Inc., the company rebranded to Kiora Pharmaceuticals, Inc. in November 2021 to better reflect its strategic focus and expanded vision for pioneering advancements in ophthalmic treatments. With a history dating back to 1998, Kiora Pharmaceuticals continues to drive innovation in the field of ophthalmology, striving to meet critical medical needs and improve patient outcomes through cutting-edge research and development efforts.